Opinion

Video

Tailoring CDK4/6 Inhibitor Treatment to Patient Needs

A leading breast cancer specialist examines the growing role of CDK4/6 inhibitors in the adjuvant treatment of HR+/HER2- early breast cancer, citing the monarchE and NATALEE trials, and explores patient and disease-related factors that guide the decision to incorporate CDK4/6 inhibitors in this context.

  1. In the adjuvant treatment of HR+/HER2- early breast cancer, endocrine therapy has traditionally played a crucial role, with CDK4/6 inhibitors becoming more prominent in recent years through the monarchE and NATALEE trials. What factors related to the patient or disease influences the decision to utilize a CDK4/6 inhibitor in this setting?
Related Videos
Screenshot of Susan Wescott, RPh, MBA
4 KOLs are featured in this series
4 KOLs are featured in this series
Justin Oldham, MD, MS, an expert on IPF
Justin Oldham, MD, MS, an expert on IPF
Screenshot of Stephanie Hsia, PharmD
1 KOL is featured in this series.
Female doctor in coat with stethoscope on blue background - Pixel-Shot - stock.adobe.com
Related Content
Fecal immunochemical test | Image credit: Paul Maguire - stock.adobe.com
October 22nd 2024

FIT Completion, Yield Rates in CRC Screening Similar After New Screening Guidelines

Julia Bonavitacola
Patients were found to have similar completion and yield rates for the fecal immunochemical test (FIT) at both 45 years and 50 years, making screening for colorectal cancer (CRC) effective in younger patients.
Managed Care Cast logo
July 18th 2024

Insurance Insights: Dr Jason Shafrin Estimates DMD Insurance Value

Brooke McCormick
On this episode of Managed Care Cast, we're talking with the author of a study published in the July 2024 issue of The American Journal of Managed Care® that estimates the insurance value of novel Duchenne muscular dystrophy (DMD) treatment.
Screenshot of an interview with Megan Ehret, PharmD
October 22nd 2024

The Latest in New and Emerging Therapies in Schizophrenia: Dr Megan Ehret

Laura Joszt, MA
In addition to Cobenfy being approved for schizophrenia, there are other drugs with novel mechanisms being studied that may mean combination therapies or, at least, more options for patients in the future.
Managed Care Cast
May 30th 2024

From Polypharmacy to Personalized Care: Dr Nihar Desai Discusses Holistic Cardiovascular Care

Giuliana Grossi
In this episode of Managed Care Cast, Nihar Desai, MD, MPH, cardiologist and vice chief of Cardiology at the Yale School of Medicine, discusses therapies for cardiovascular conditions as they relate to patient adherence, polypharmacy, and health access.
Clinician giving patient a diagnosis | Image Credit: Pcess609 - stock.adobe.com
October 21st 2024

Lower Diagnostic Error Rates Found Among Hospitalized Patients During Care Transitions

Brooke McCormick
Examining care transitions in hospitalized patients revealed lower diagnostic error rates compared with traditional methods, highlighting the effectiveness of this approach in identifying diagnostic challenges.
Image with AJMC Q&A and the headshot of Daniel Wolff, MD
Published: October 18th 2024 | Updated: October 18th 2024

A Novel Approach to Chronic GVHD With Axatilimab: Dr Daniel Wolff

Laura Joszt, MA
The latest therapy approved to treat chronic graft-versus-host disease (GVHD) has a new target different than the other approved therapies. Daniel Wolff, MD, also discusses future research on axatilimab to treat chronic GVHD earlier.

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2024 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo